Sign In

David Cory

Chief Executive Officer, LIB Therapeutics

David Cory is an accomplished professional with a diverse background in the pharmaceutical and biotechnology industries. He holds a degree in College of Pharmacy, with a specialization in Medicinal and Pharmaceutical Chemistry from the University of Cincinnati. Additionally, he pursued a Masters in Business Administration focusing on Finance and Management at the University of Maryland.

Highlights

Dec 7 · linkedin

I am pleased to welcome Ingrid Choong, PhD to the LIB Therapeutics executive team at this important stage of our evolution toward becoming a commercial-stage company.  She brings a broad set of operational experience to the LIB team to support our goal of rapid global access to Lerodalcibep through multiple pathways including strategic partnerships and commercial preparation.  Ingrid has a tremendous passion for helping patients and I am pleased that she has decided to join our incredible team at LIB Therapeutics.

Lerodalcibep is a novel, third generation PCSK9 inhibitor in development to reduce low density lipoprotein-cholesterol and prevent and treat cardiovascular disease, and has now completed Phase 3 registration-enabling studies (N=2,387).  BLA submission is planned for 1H 2024.

Nov 16 · linkedin

This week, we were excited to announce that LIB Therapeutics has completed the global Phase 3 registration-enabling LIBERATE program including 4 key pivotal studies (N=2,387) dosing up to 52 weeks for Lerodalcibep, a novel, third-generation PCSK9 inhibitor developed to treat and prevent cardiovascular disease. 

The global PCSK9 market will approach $3B in net sales in 2023 and is projected to be $5B in 2025.

We look forward to working with regulators to submit a BLA and MAA in 1H 2024.

David Cory
Add to my network

Location

United States